- Home
- HBIO vs NRXS Comparison
HBIO vs NRXS Comparison
Compare HBIO & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HBIO
- NRXS
- Stock Information
- Founded
- HBIO 1901
- NRXS 2011
- Country
- HBIO United States
- NRXS United States
- Employees
- HBIO N/A
- NRXS N/A
- Industry
- HBIO Biotechnology: Laboratory Analytical Instruments
- NRXS
- Sector
- HBIO Industrials
- NRXS
- Exchange
- HBIO Nasdaq
- NRXS Nasdaq
- Market Cap
- HBIO 24.6M
- NRXS 25.0M
- IPO Year
- HBIO 2000
- NRXS 2023
- Fundamental
- Price
- HBIO $0.44
- NRXS $2.33
- Analyst Decision
- HBIO Buy
- NRXS Strong Buy
- Analyst Count
- HBIO 3
- NRXS 1
- Target Price
- HBIO $2.50
- NRXS $7.00
- AVG Volume (30 Days)
- HBIO 457.4K
- NRXS 37.0K
- Earning Date
- HBIO 11-06-2025
- NRXS 11-11-2025
- Dividend Yield
- HBIO N/A
- NRXS N/A
- EPS Growth
- HBIO N/A
- NRXS N/A
- EPS
- HBIO N/A
- NRXS N/A
- Revenue
- HBIO $88,750,000.00
- NRXS $3,217,531.00
- Revenue This Year
- HBIO N/A
- NRXS $62.14
- Revenue Next Year
- HBIO $7.13
- NRXS $131.87
- P/E Ratio
- HBIO N/A
- NRXS N/A
- Revenue Growth
- HBIO N/A
- NRXS 41.93
- 52 Week Low
- HBIO $0.28
- NRXS $1.33
- 52 Week High
- HBIO $3.04
- NRXS $6.20
- Technical
- Relative Strength Index (RSI)
- HBIO 40.70
- NRXS 40.42
- Support Level
- HBIO $0.49
- NRXS $2.40
- Resistance Level
- HBIO $0.47
- NRXS $2.49
- Average True Range (ATR)
- HBIO 0.03
- NRXS 0.11
- MACD
- HBIO -0.01
- NRXS -0.01
- Stochastic Oscillator
- HBIO 13.00
- NRXS 5.41
About HBIO Harvard Bioscience Inc.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, pharmaceutical and therapy discovery, bioproduction, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life sciences and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, and Panlab. The majority of its revenue comes from the United States.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).